The relationship between amyloid deposition, neurodegeneration, and cognitive decline in dementia topical collection on neuroimaging

Current Neurology and Neuroscience Reports

Volumn 14, Issue 11, 2014, Pages

  Vandenberghe, Rik ^a,b,c  

^a KU LEUVEN UNIVERSITY OF LEUVEN   (Belgium)

^b UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^c UNIVERSITY OF LEUVEN   (Belgium)

Author keywords

Alzheimer; Florbetaben; Florbetapir; Flutemetamol; MCI; Preclinical

Indexed keywords

AMYLOID BETA PROTEIN; APOLIPOPROTEIN E4; F ACTIN; FLORBETABEN; FLORBETAPIR F 18; FLUTEMETAMOL F 18; TAR DNA BINDING PROTEIN; TAU PROTEIN; AMYLOID;

AGING; ALZHEIMER DISEASE; AMYLOID PLAQUE; AMYLOIDOSIS; ARTICLE; BRAIN REGION; BRAIN SIZE; CONNECTOME; DEMENTIA; DISEASE MARKER; ELECTROENCEPHALOGRAM; FUNCTIONAL MAGNETIC RESONANCE IMAGING; HUMAN; IN VIVO STUDY; LEWY BODY; MENTAL DETERIORATION; MILD COGNITIVE IMPAIRMENT; NERVE DEGENERATION; NEUROIMAGING; POSITRON EMISSION TOMOGRAPHY; PROTEIN AGGREGATION; TASK PERFORMANCE; TDP 43 PROTEINOPATHY; COGNITION DISORDERS; COMPLICATION; DEGENERATIVE DISEASE; METABOLISM;

AMYLOID; COGNITION DISORDERS; DEMENTIA; HUMANS; NEURODEGENERATIVE DISEASES;

EID: 84961307189     PISSN: 15284042     EISSN: 15346293     Source Type: Journal    
DOI: 10.1007/s11910-014-0498-9     Document Type: Article

References (92)

1. Klunk WE, Engler H, Nordberg A, Wang Y, Blomqvist G, Holt D, et al. Imaging brain amyloid in Alzheimer's disease with Pittsburgh compound-B. Ann Neurol. 2004;55:306-19.
2. 18F-florbetapir as a marker of neuritic amyloid plaque density.
3. Rowe CC, Villemagne VL. Brain amyloid imaging. J Nucl Med Technol. 2013;41:11-8.
4. Vandenberghe R, Adamczuk K, Dupont P, Van Laere K, Chételat G. Amyloid PET in clinical practice: Its place in the multidimensional space of Alzheimer's disease. Neuroimage Clin. 2013;2:497-511.
5. Rinne J, Brooks DJ, Rossor MN, Fox NC, Bullock R, Klunk WE, et al. (11)C-PIB PET assessment of change in fibrillar amyloid-beta load in patients with Alzheimer's disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose study. Lancet Neurol. 2010;9:363-72.
6. Ostrowitzki S, Deptula D, Thurfjell L, Barkhof F, Bohrmann B, Brooks DJ, et al. Mechanism of amyloid removal in patients with Alzheimer disease treated with gantenerumab. Arch Neurol. 2012;69:198-207.
7. Salloway S, Sperling R, Fox NC, Blennow K, Klunk WE, Raskind M, et al. Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer's disease. N Engl J Med. 2014;370:322-33.
8. 18∈F-flutemetamol amyloid imaging in Alzheimer disease and mild cognitive impairment: a phase 2 trial. Ann Neurol. 2010;68:319-29.
9. 18PET and 18-month cognitive decline: a multicenter study. Neurology. 2012;79:1636-44.
10. Petersen RC, Aisen P, Boeve BF, Geda YE, Ivnik RJ, Knopman DS, et al. Mild cognitive impairment due to Alzheimer disease in the community. Ann Neurol. 2013;74:199-208.
11. Beach TG, Monsell SE, Phillips LE, Kukull W. Accuracy of the clinical diagnosis of Alzheimer disease at National Institute on Aging Alzheimer Disease centers, 2005-2010. J Neuropathol Exp Neurol. 2012;71:266-73. This clinicopathological paper provides critical information about the accuracy of a clincal diagnosis of clinically probable or possible AD in a prospective multicentre academic memory clinic based series collected between 2005 and 2010 (n∈=∈919). Compared to the standard-of-truth (neuritic plaque density and neurofibrillary tangle stage), the positive predictive value of a diagnosis of clinically probable AD ranged between 62 and 84 %; specificity between 60 % to 71 %, with a sensitivity around 73 %.
12. Vandenberghe R, Adamczuk K, Van Laere K. The interest of amyloid PET imaging in the diagnosis of Alzheimer's disease. Curr Opin Neurol. 2013;26:646-55.
13. Edison P, Rowe CC, Rinne JO, Nq S, Ahmed I, Kemmpainen N, et al. Amyloid load in Parkinson's disease dementia and Lewy body dementia measured with [11C]PIB positron emission tomography. J Neurol Neurosurg Psychiatry. 2008;79:1331-8.
14. Gomperts SN. Imaging the role of amyloid in PD dementia and dementia with Lewy bodies. Curr Neurol Neurosci Rep. 2014;14:472.
15. Kantarci K, Lowe VJ, Boeve BF, Weigand SD, Senjem ML, Przybelski SA, et al. Multimodality imaging characteristics of dementia with Lewy bodies. Neurobiol Aging. 2012;33:2091-105.
16. Bettens K, Sleegers K, Van Broeckhoven C. Current status on Alzheimer disease molecular genetics: from past, to present, to future. Hum Mol Genet. 2010;19:R4-R11.
17. Savva GM, Wharton SB, Ince PG, Forster G, Matthews FE, Brayne C, et al. Age, neuropathology, and dementia. N Engl J Med. 2009;360:2302-9.
18. Jack CR, Knopman DS, Jagust WJ, Petersen RC, Weiner MW, Aisen PS, et al. Tracking pathophysiological processes in Alzheimer's disease: an updated hypothetical model of dynamic biomarkers. Lancet Neurol. 2013;12:207-16.
19. Hardy J, Selkoe DJ. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science. 2002;297:353-6.
20. Oddo S, Caccamo A, Shepherd JD, Murphy MP, Golde TE, Kayed R, et al. Triple-transgenic model of Alzheimer's disease with plaques and tangles: intracellular Aβ and synaptic dysfunction. Neuron. 2003;39:409-21.
21. Silbert LC, Quinn JF, Moore MM, Corbridge E, Ball MJ, Murdoch G, et al. Changes in premorbid brain volume predict Alzheimer's disease pathology. Neurology. 2003;61:487-92.
22. Jagust WJ, Zheng L, Harvey DJ, Mack WJ, Vinters HV, Weiner MW, et al. Neuropathological basis of magnetic resonance images in aging and dementia. Ann Neurol. 2008;63:72-80.
23. Josephs KA, Whitwell JL, Ahmed Z, Shiung MM, Weigand SD, Knopman DS, et al. Beta-amyloid burden is not associated with rates of brain atrophy. Ann Neurol. 2008;63:204-12.
24. Sabuncu MR, Desikan RS, Sepulcre J, Yeo BTT, Liu H, Schmansky NJ, et al. The dynamics of cortical and hippocampal atrophy in Alzheimer disease. Arch Neurol. 2011;68:1040-8.
25. Erten-Lyons D, Dodge HH, Woltjer R, Silbert LC, Howieson DB, Kramer P, et al. Neuropathologic basis of age-associated brain atrophy. JAMA Neurol. 2013;70:616-22. From the Oregon Brain and Aging study, different measures (ventricular, total brain and hippocampal) were derived from longitudinal structural MRIs obtained in 70 cognitively intact older adults. These were correlated with clinical status, APOE status and neuropathological measures (NFT, neuritic plaques, different types of vascular lesions). Strongest correlations were obtained for ventricular and total brain measures. The correlations between these structural measures and cognition remained even after controlling for the degree of neuropathology. Hippocampal volume correlated only with the degree of amyloid angiopathy.
26. MC Donohue, H Jacqmin-Gadda, M Le Goff, RG Thomas, R Raman, AC Gamst, et al. Estimating long-term multivariate progression from short-term data. Alzheimers Dement. in press, 2014.
27. M Bilgel, Y An, A Lang, J Prince, L Ferrucci, B Jedynak, and SM Resnick. Trajectories of Alzheimer disease-related cognitive measures in a longitudinal sample. Alzheimers Dement. in press, 2014. Ultimately, efficacy of any intervention must be proven in terms of clinical parameters. From almost 900 BLSA participants, some of the most commonly used neuropsychological episodic memory measures were analyzed for their sensitivity to detect decline in the preclinical AD stage. The importance of this work lies in the high familiarity worldwide of the test parameters examined and the novel insight into the relative sensitivity of encoding versus retrieval parameters
28. Dickerson BC, Bakkour A, Salat DH, Feczko E, Pacheco J, Greve DN, et al. The cortical signature of Alzheimer's disease: regionally specific cortical thinning relates to symptom severity in very mild to mild AD dementia and is detectable in asymptomatic amyloid-positive individuals. Cereb Cortex. 2009;19:497-510.
29. Vlassenko AG, Mintun MA, Xiong C, Sheline YI, Goate AM, Benzinger TLS, et al. Amyloid-beta plaque growth in cognitively normal adults: longitudinal [11C]Pittsburgh compound B data. Ann Neurol. 2011;70:857-61.
30. Villain N, Chételat G, Grassiot B, Bourgeat P, Jones G, Ellis KA, et al. Regional dynamics of amyloid-β deposition in healthy elderly, mild cognitive impairment and Alzheimer's disease: a voxelwise PIB-PET longitudinal study. Brain. 2012;135:2126-39.
31. Villemagne VL, Burnham S, Bourgeat P, Brown B, Ellis KA, Salvado O, et al. Amyloid β deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer's disease: a prospective cohort study. Lancet Neurol. 2013;12:357-67.
32. Jack CR, Wiste HJ, Knopman DS, Vemuri P, Mielke MM, Weigand SD, et al. Rates of β-amyloid accumulation are independent of hippocampal neurodegeneration. Neurology. 2014;82:1605-12.
33. Chételat G, Villemagne VL, Villain N, Jones G, Ellis KA, Ames D, et al. Accelerated cortical atrophy in cognitively normal elderly with high β-amyloid deposition. Neurology. 2012;78:477-84.
34. Bateman RJ, Xiong C, Benzinger TLS, Fagan AM, Goate A, Fox NC, et al. Clinical and biomarker changes in dominantly inherited Alzheimer's disease. N Engl J Med. 2012;367:795-804. From the Dominantly Inherited Alzheimer Network, multimodal cross-sectional data were analyzed from 50 symptomatic and 50 asymptomatic mutation carriers and 100 noncarrier siblings. This study provides critical empirical evidence for the orderly sequence of changes in in vivo biomarkers in monogenic AD up to 30 years prior to expected disease onset.
35. Fleisher AS, Chen K, Quiroz YT, Jakimovich LJ, Gomez MG, Langois CM, et al. Florbetapir PET analysis of amyloid-β deposition in the Presenilin 1 E280A autosomal dominant Alzheimer's disease kindred: a cross-sectional study. Lancet Neurol. 2012;11:1057-65.
36. Reiman EM, Quiroz YT, Fleisher AS, Chen K, Velez-Pardo C, Jimenez-Del-Rio M, et al. Brain imaging and fluid biomarker analysis in young adults at genetic risk for autosomal dominant Alzheimer's disease in the Presenilin 1 E280A kindred: a case-control study. Lancet Neurol. 2012;11:1048-56. From the Columbian Alzheimer Prevention Initiative registry, 20 PS1 mutation carriers and 20 noncarrier siblings between 18 and 26 years of age underwent task-related fMRI, structural MRI and CSF. This study provides essential insight in the functional organization of cognitive brain systems prior to clinical disease expression.
37. Fagan AM, Xiong C, Jasielec MS, Bateman RJ, Goate AM, Benzinger TLS, et al. Longitudinal change in CSF biomarkers in autosomal-dominant Alzheimer's disease. Sci Transl Med. 2014;6:226-30.
38. B Kaur, JJ Himali, S Seshadri, AS Beiser, R Au, AC McKee, et al. Association between neuropathology and brain volume in the Framingham Heart Study. Alzheimer Dis Assoc Disord. in press, 2014.
39. Fotuhi M, Do D, Jack C. Modifiable factors that alter the size of the hippocampus with ageing. Nat Rev Neurol. 2012;8:189-202.
40. Wilson RS, Yu L, Trojanowski JQ, Chen EY, Boyle PA, Bennett DA, et al. TDP-43 pathology, cognitive decline, and dementia in old age. JAMA Neurol. 2013;70:1418-24. In a consecutive series of 130 cases with annual cognitive assessments for more than 10 years, postmortem measures of TDP43 explained as much variability in the rate of the cognitive decline as neurofibrillary tangles. This is of high importance as it points to high clinical relevance of other proteinopathies apart from the classical AD hallmark lesions.
41. Gomez-Isla T, Price JL, McKeel DW, Morris JC, Growdon JH, Hyman BT. Profound loss of layer II entorhinal cortex neurons occurs in very mild Alzheimer's disease. J Neurosci. 1996;16:4491-500.
42. Braak H, Braak E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol. 1991;82:239-59.
43. Hyman BT, Gomez-Isla T. Alzheimer's disease is a laminar, regional, and neural system specific disease, not a global brain disease. Neurobiol Aging. 1994;15:353-4.
44. Braak H, Thal DR, Ghebremedhin E, Del Tredici K. Stages of the pathologic process in Alzheimer disease: age categories from 1 to 100 years. J Neuropathol Exp Neurol. 2011;70:960-9.
45. DeKosky ST, Scheff SW. Synapse loss in frontal cortex biopsies in Alzheimer's disease: correlation with cognitive severity. Ann Neurol. 1990;27:457-64.
46. Terry RD, Masliah E, Salmon DP, Butters N, DeTeresa R, Hill R, et al. Physical basis of cognitive alterations in Alzheimer's disease: Synapse loss is the major correlate of cognitive impairment. Ann Neurol. 1991;30:572-80.
47. Davis DG, Schmitt FA, Wekstein DR, Markesberry WR. Alzheimer neuropathologic alterations in aged cognitively intact subjects. J Neuropathol Exp Neurol. 1999;58:376-88.
48. Scheff SW, Price DA, Schmitt FA, Mufson EJ. Hippocampal synaptic loss in early Alzheimer's disease and mild cognitive impairment. Neurobiol Aging. 2006;27:1372-84.
49. Kovacs GG, Milenkovic I, Wöhrer A, Höftberger R, Gelpi E, Haberler C, et al. Non-Alzheimer neurodegenerative pathologies and their combinations are more frequent than commonly believed in the elderly brain: a community-based autopsy series. Acta Neuropathol. 2013;126:365-84.
50. Snowdon DA, Greiner LH, Mortimer JA, Riley KP, Greiner PA, Markesbery WR. Brain infarction and the clinical expression of Alzheimer's disease: The Nun study. JAMA. 1997;277:813-7.
51. Schneider JA, Arvanitakis Z, Yu L, Boyle PA, Leurgans SE, Bennett DA. Cognitive impairment, decline and fluctuations in older community-dwelling subjects with Lewy bodies. Brain. 2012;135:3005-14.
52. Kovacs G. Current concepts of neurodegenerative diseases. Eur Med J Neurol. 2014;1:78-86.
53. Boyle PA, Wilson RS, Yu L, Barr AM, Honer WG, Schneider JA, et al. Much of late life cognitive decline is not due to common neurodegenerative pathologies. Ann Neurol. 2013;74:478-89.
54. Iacono D, Resnick SM, O'Brien R, Zonderman AB, An Y, Pletnikova O, et al. Mild cognitive impairment and asymptomatic Alzheimer disease subjects: equivalent β-amyloid and tau loads with divergent cognitive outcomes. J Neuropathol Exp Neurol. 2014;73:295-304.
55. Dickerson BC, Sperling RA. Large-scale functional brain network abnormalities in Alzheimer's disease: insights from functional neuroimaging. Behav Neurol. 2009;21:63-75.
56. Quiroz YT, Budson AE, Celone K, Ruiz A, Newmark R, Castrillón G, et al. Hippocampal hyperactivation in presymptomatic familial Alzheimer's disease. Ann Neurol. 2010;68:865-75.
57. Jagust WJ, Mormino EC. Lifespan brain activity, β-amyloid, and Alzheimer's disease. Trends Cogn Sci. 2011;15:520-6.
58. Vandenbulcke M, Peeters R, Dupont P, Van Hecke P, Vandenberghe R. Word reading and posterior temporal dysfunction in amnestic mild cognitive impairment. Cereb Cortex. 2007;17:542-51.
59. Nelissen N, Vandenbulcke M, Fannes K, Verbruggen A, Peeters R, Dupont P, et al. Aβ amyloid deposition in the language system and how the brain responds. Brain. 2007;130:2055-69.
60. Becker JT, Mintun MA, Aleva K, Wiseman MB, Nichols T, DeKosky ST. Compensatory reallocation of brain resources supporting verbal episodic memory in Alzheimer's disease. Neurology. 1996;46:692-700.
61. Grady CL, McIntosh AR, Beig S, Keightley ML, Burian H, Black SE. Evidence from functional neuroimaging of a compensatory prefrontal network in Alzheimer's disease. J Neurosci. 2003;23:986-93.
62. Mintun MA, Larossa GN, Sheline YI, Dence CS, Lee SY, Mach RH, et al. [11C]PIB in a nondemented population: potential antecedent marker of Alzheimer disease. Neurology. 2006;67:446-52.
63. Pike KE, Savage G, Villemagne VL, Ng S, Moss SA, Maruff P, et al. Beta-amyloid imaging and memory in non-demented individuals: evidence for preclinical Alzheimer's disease. Brain. 2007;130:2837-44.
64. Aizenstein HJ, Nebes RD, Saxton JA, Price JC, Mathis CA, Tsopelas ND, et al. Frequent amyloid deposition without significant cognitive impairment among the elderly. Arch Neurol. 2008;65:1509-17.
65. Adamczuk K, De Weer AS, Nelissen N, Chen K, Sleegers K, Bettens K, et al. Polymorphism of brain derived neurotrophic factor influences β amyloid load in cognitively intact apolipoprotein e ε4 carriers. Neuroimage Clin. 2013;2:512-20.
66. Fleisher AS, Chen K, Liu X, Ayutyanont N, Roontiva A, Thiyyagura P, et al. Apolipoprotein E ε4 and age effects on florbetapir positron emission tomography in healthy aging and Alzheimer disease. Neurobiol Aging. 2013;34:1-12. Based on a pooled analysis of 245 subjects who had undergone 18 F-florbetapir and APOE genotyping, reliable age-dependent estimates are obtained for linear amyloid increase and for amyloid-positivity as a function of age and APOE.
67. Yeo BTT, Krienen FM, Sepulcre J, Sabuncu MR, Lashkari D, Hollinshead M, et al. The organization of the human cerebral cortex estimated by intrinsic functional connectivity. J Neurophysiol. 2011;106:1125-65.
68. Buckner RL, Snyder AZ, Shannon BJ, LaRossa G, Sachs R, Fotenos AF, et al. Molecular, structural, and functional characterization of Alzheimer's disease: evidence for a relationship between default activity, amyloid, and memory. J Neurosci. 2005;25:7709-17.
69. Seeley WW, Crawford RK, Zhou J, Miller BL, Greicius MD. Neurodegenerative diseases target large-scale human brain networks. Neuron. 2009;62:42-52.
70. Zhou J, Gennatas ED, Kramer JH, Miller BL, Seeley WW. Predicting regional neurodegeneration from the healthy brain functional connectome. Neuron. 2012;73:1216-27.
71. Myers N, Pasquini L, Göttler J, Grimmer T, Koch K, Ortner M, et al. Within-patient correspondence of amyloid-β and intrinsic network connectivity in Alzheimer's disease. Brain. 2014;137:2052-64.
72. Vlassenko AG, Vaishnavi SN, Couture L, Sacco D, Shannon BJ, Mach RH, et al. Spatial correlation between brain aerobic glycolysis and amyloid-β deposition. Proc Natl Acad Sci U S A. 2010;107:17763-7.
73. Mathis CA, Kuller LH, Klunk WE, Snitz BE, Price JC, Weissfeld LA, et al. In vivo assessment of amyloid-β deposition in nondemented very elderly subjects. Ann Neurol. 2013;73:751-61.
74. G Chételat, R La Joie, N Villain, A Perrotin, V de La Sayette, F Eustache, and R Vandenberghe. Amyloid imaging in cognitively normal individuals, at-risk populations and preclinical Alzheimer's disease. NeuroImage: Clinical. 2013
75. Dubois B, Feldman HH, Jacova C, Hampel H, Molinuevo JL, Blennow K, et al. Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria. Lancet Neurol. 2014;13:614-29.
76. Altmann A, Tian L, Henderson VW, Greicius MD, Alzheimer's Disease Neuroimaging Initiative Investigators. Sex modifies the APOE-related risk of developing Alzheimer disease. Ann Neurol. 2014;75:563-73.
77. Morris JC, Roe CM, Xiong C, Fagan AM, Goate AM, Holtzman DM, et al. APOE predicts amyloid-beta but not tau Alzheimer pathology in cognitively normal aging. Ann Neurol. 2010;67:122-31.
78. Thambisetty M, An Y, Nalls M, Sojkova J, Swaminathan S, Zhou Y, et al. Effect of complement CR1 on brain amyloid burden during aging and its modification by APOE genotype. Biol Psychiatry. 2013;73:422-8.
79. Sperling RA, Aisen P, Beckett LA, Bennett DA, Craft S, Fagan AM, et al. Toward defining the preclinical stages of Alzheimer's disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement. 2011;7:280-92.
80. 18∈F-flutemetamol PET using machine learning: Comparison with visual reads and structural MRI. Neuroimage. 2012;64C:517-25.
81. Jack CR, Knopman DS, Weigand SD, Wiste HJ, Vemuri P, Lowe V, et al. An operational approach to National Institute on Aging-Alzheimer's Association criteria for preclinical Alzheimer disease. Ann Neurol. 2012;71:765-75.
82. Knopman DS, Jack Jr CR, Wiste HJ, Weigand SD, Vemuri P, Lowe VJ, et al. Brain injury biomarkers are not dependent on β-amyloid in normal elderly. Ann Neurol. 2013;73:472-80.
83. Becker JA, Hedden T, Carmasin J, Maye J, Rentz DM, Putcha D, et al. Amyloid-β associated cortical thinning in clinically normal elderly. Ann Neurol. 2011;69:1032-42.
84. Sheline YI, Raichle ME, Snyder AZ, Morris JC, Head D, Wang S, et al. Amyloid plaques disrupt resting state default mode network connectivity in cognitively normal elderly. Biol Psychiatry. 2010;67:584-7.
85. Knopman DS. CR Jack, Jr, H. J. Wiste, S. D. Weigand, P. Vemuri, V. Lowe, et al. Short-term clinical outcomes for stages of NIA-AA preclinical Alzheimer disease. Neurology. 2012;78:1576-82.
86. Lim YY, Villemagne VL, Laws SM, Ames D, Pietrzak RH, Ellis KA, et al. BDNF val66met, Aβ amyloid, and cognitive decline in preclinical Alzheimer's disease. Neurobiol Aging. 2013;34:2457-64.
87. Nordberg A, Carter SF, Rinne J, Drzezga A, Brooks DJ, Vandenberghe R, et al. A European multicentre PET study of fibrillar amyloid in Alzheimer's disease. Eur J Nucl Med Mol Imaging. 2013;40:104-14.
88. Jack CR, Wiste HJ, Vemuri P, Weigand SD, Senjem ML, Zeng G, et al. Brain beta-amyloid measures and magnetic resonance imaging atrophy both predict time-to-progression from mild cognitive impairment to Alzheimer's disease. Brain. 2010;133:3336-48.
89. Villemagne VL, Pike KE, Chételat G, Ellis KA, Mulligan RS, Bourgeat P, et al. Longitudinal assessment of Aβ and cognition in aging and Alzheimer disease. Ann Neurol. 2011;69:181-92.
90. Rowe CC, Bourgeat P, Ellis KA, Brown B, Lim YY, Mulligan R, et al. Predicting Alzheimer disease with β-amyloid imaging: results from the Australian Imaging, Biomarkers, and Lifestyle study of ageing. Ann Neurol. 2013;74:905-13.
91. Duara R, Loewenstein DA, Shen Q, Barker W, Potter E, Varon D, et al. Amyloid positron emission tomography with (18)F-flutemetamol and structural magnetic resonance imaging in the classification of mild cognitive impairment and Alzheimer's disease. Alzheimers Dement. 2013;9:295-301.
92. Jack Jr CR, Wiste HJ, Lesnick TG, Weigand SD, Knopman DS, Vemuri P, et al. Brain β-amyloid load approaches a plateau. Neurology. 2013;80:890-6.